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For those of us who participate in the ﬁght against malaria,
the present time stands in stark contrast to what we have
always known. In comparison with the eve of this century,
less than a dozen year ago, there is presently some unani-
mously accepted good news. The global burden of malarial
disease has been reduced in a large variety of settings,
regardless of transmission intensities and endemic patterns.
Malaria prevalence, morbidity and mortality are now low
enough in several areas of tropical Africa to challenge some
well-established principles of malariology.
There are three major reasons for this welcome improve-
ment: (i) the unprecedented increase in funding devoted to
malaria control; (ii) generalization of the shift from chloro-
quine to artemisinin-based combination therapy for the
treatment of clinical malaria attacks; and (iii) deployment of a
much better prevention strategy, largely owing to insecti-
cide-treated bed-nets and, in some places, to residual wall
spraying with insecticides.
Two other approaches also proved to be very effective
where they were deployed: intermittent preventive treat-
ment, probably equivalent to targeted chemoprophylaxis,
focused at the two most vulnerable populations—pregnant
women and children; and improvement of case detection
with rapid diagnostic test kits that are easily usable at the
patient’s bedside by both local health workers and nurses.
Although prompt access to effective drugs has been
shown to prevent most malaria deaths, even in a context of
intense malaria transmission, and the implementation of
insecticide-treated nets has dramatically reduced the burden
of malaria, there is no doubt that the combination of differ-
ent interventions has had a synergistic effect, resulting in a
much higher impact than the separate use of individual con-
trol measures.
Forty countries worldwide have recently reduced malaria
deaths and cases by half. Some countries, such as Morocco,
have recently eliminated malaria completely, and others have
made impressive progress, such as South Africa and Swazi-
land, where cases have decreased by approximately 90%. A
recent report on malaria research underlines that investment
has more than quadrupled in the past 16 years, from
US$121 million in 1993 to US$612 million in 2009 [1].
Between 2004 and 2009, 28% of this funding was used for
vaccine development, 38% for new drugs or combinations of
drugs, 23% for basic research, but only 4% for vector control
products (mainly new insecticides) and 1% for new diagnostic
testing systems. This contrasting picture largely reﬂects the
donor funding preferences.
In this special issue of Clinical Microbiology and Infection,
devoted to malaria elimination, Brian Greenwood and
Geoffrey Targett provide deﬁnitions of malaria control,
elimination and eradication, before they focus on malaria
vaccines and explain why second-generation vaccines are
needed even though the ﬁrst malaria vaccine has not yet
been licensed [2]. Meredith McMorrow [3] emphasizes the
importance of malaria diagnostic tests in the context of
elimination, and discusses how these tests are useful and
what improvements are needed in the future. Roly
Gosling, Lucy Okell, Jacklin Mosha and Daniel Chandramo-
han express their views on active case detection and
malaria treatment for clinical cases, as well as asymptom-
atic parasite carriers. Unsurprisingly, modelling approaches
advocate maximum efﬁcacy when drug administration pro-
grammes are implemented at the same time as antivector
activities [4]. Kaliyaperumal Karunamoorthi [5] focuses on
vector control measures. Since the pioneering studies that
discovered the efﬁcacy of bed-nets when they were trea-
ted by dipping them in pyrethroid insecticides [6,7], long-
lasting factory-coated or impregnated bed-nets have been
developed that do not need to be repeatedly impregnated.
Indoor and/or outdoor residual spraying with insecticides
constitutes the second main tool for vector control. Many
other vector control tools exist, but are used on a much
smaller scale or remain at the stage of proof-of-concept [8].
The remarkable successes achieved in malaria elimination
must not be allowed to disguise their delicate nature [9].
Elimination, by deﬁnition, implies that both capacity and
commitment are needed to sustain this status indeﬁnitely
[10].
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The major current potential barrier to malaria elimination
lies within uncertainties concerning the durability of fund-
ing: only two organizations, the Bill and Melinda Gates
Foundation and the US National Institutes of Health, pro-
vided half of the global malaria research and development
funding in 2007–2009 [1]. Malaria control activities are
mainly funded by multilateral or bilateral initiatives, includ-
ing the Global Fund, the World Bank Malaria Booster Pro-
gram, and the US President’s Malaria Initiative, that
depend heavily on the involvement of the governments of
developed nations and are therefore subject to changing
political and economic priorities. There is an urgent need
for new innovative and sustainable ﬁnancing mechanisms,
such as the UNITAID initiative (http://www.unitaid.eu),
launched by France and Brazil in 2006 (UNITAID groups
29 committed countries, receives its funds through airline
ticket taxes or regular budget contributions, and contrib-
utes to the scaling up of access to treatment in the poor-
est countries).
A second concern is resistance to artemisinin, which has
been detected in the region of the Thai/Cambodia border,
underlining the ongoing need for new drugs/combined
therapies. In parallel, the increase in the pan-global detec-
tion of pyrethroid resistance in a number of populations
of malaria vectors is also worrying, as recently established
in Senegal, where a rebound in malaria morbidity following
the emergence of pyrethroid resistance in Anopheles gam-
biae was observed [11]. The fragility of the available tools
for ﬁghting malaria, and the need for the development of
new tools to achieve Plasmodium falciparum elimination,
must be recognized. This is the case in tropical Africa,
where control is not easy, mainly because the anopheline
vectors are the most efﬁcient in the world. A. gambiae
exhibits a huge and challenging vectorial capacity: even
very low gametocyte frequencies in the community may
sustain high entomological inoculation rates where this
vector is present. Achievement of Plasmodium vivax elimi-
nation is subject to another set of problems, mainly
because of the dormant hypnozoite stage and the limita-
tions of primaquine, the only available drug against the
liver-stage parasite [12].
A third concern is our lack of knowledge. A major gap is
our poor understanding of the mechanisms and conditions
of the likely rebound or resurgence of disease if control
measures are reduced. Historical observations in Ethiopia
[13] and Sri Lanka [14] have shown how the malaria situa-
tion can worsen rapidly and dramatically in the context of
unanimously recognized successes. Vast areas of uncer-
tainty remain to be investigated, such as: the importance
of heterogeneity of contact between humans and mosqui-
toes, resulting in a small proportion of people receiving a
large proportion of parasite inoculations; Plasmodium trans-
mission by exophilic vectors; the potential reservoir of
human-infective parasites in apes and monkeys; the R0 (the
basic reproductive number, i.e. the number of secondary
cases of malaria arising from a single case) in a context of
near-zero immunity; and the capacity of mass drug admin-
istration for elimination-speciﬁc intervention.
Once elimination has been achieved, measures aimed at
preventing imported infections must be implemented and
maintained. These measures imply coercive interventions
that are only possible if public health administration is suf-
ﬁciently stringent and effective. Some isolated areas (e.g.
islands such as Mauritius, Zanzibar and Bioko, or northern
Africa vs. tropical Africa, with restricted exchanges owing
to the natural boundary of the Sahara) may be less vulner-
able to re-invasion. A more negative scenario is where
neighbouring countries have very different and perhaps
incompatible control/elimination statuses, leading to much
more complex situations with a high frequency of re-
invading malarial parasites via both infected people and
mosquitoes.
Because maintenance of the measures requires strong and
stable governments, achieving and maintaining elimination
cannot be considered independently of the social and
political developments in malaria-endemic countries. These
developments constitute a necessary condition for malaria
elimination that lies outside the present scope of any
malaria elimination programme.
Today, some 67 countries worldwide are involved in the
control of endemic malaria; 32 are considered to be malaria-
eliminating countries, with the dominant challenge of elimi-
nating P. vivax parasites, and a further 109 countries are
malaria-free (79 of which have eliminated malaria since
1945). Prominent colleagues [15] accept that all malaria-elim-
inating countries have a reasonable prospect of achieving
elimination within the next decade or so. In many other
countries, it seems feasible to eliminate malaria transmission
in highland, mountainous, semi-arid and urbanized areas [16].
The massive urbanization process that has been occurring in
Africa since the mid-1960s is likely to improve the prospects
for malaria elimination on a local scale [17], because more
and more people will live with a lower risk of infection. They
should then be considered as non-immune travellers when
moving elsewhere within the country, i.e. be subject to pro-
phylactic measures recommended to travellers [18].
There is growing evidence that elimination of the trans-
mission of the malarial parasites, at national or subnational
levels, is occurring. This is a great cause for celebration in
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the short term. However, bearing in mind the lessons of the
past [19], no one envisions a future in which eradication is a
certainty.
Talking prematurely of malaria eradication is a double-
edged sword. Positive aspects are numerous, and among
them are: the necessary reminder that eradication is the ﬁnal
goal; and the fact that civil society, the political community
and the fund donors easily understand the concept [20]. In
Seattle in October 2007, Melinda Gates rightly proclaimed in
her address to researchers and policy-makers from around
the world: ‘Bill and I believe that these advances in science
and medicine, your promising research, and the rising con-
cern of people around the world represent a historic oppor-
tunity not just to treat malaria or to control it—but to chart
a long-term course to eradicate it.’ Unfortunately, negative
aspects are also numerous: talk of eradication implies that
the tools and knowledge needed to achieve the objective will
be available in any country and situation, and that eradication
can be readily achieved without exception around the world.
To avoid huge disappointment, those actively working
towards malaria elimination must maintain realistic expecta-
tions. They must be aware of the limitations of their inter-
ventions, especially with regard to their durability and
maintenance, without a deﬁned endpoint in a changing and
unstable world.
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